For the quarter ending 2025-09-30, ITRM had -$2,029K decrease in cash & cash equivalents over the period. -$7,459K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -8,979 | -11,400 |
| Depreciation | 6 | 13 |
| Amortization of intangible asset | 349 | 687 |
| Share-based compensation expense | 53 | 117 |
| Interest on short-term investments | 0 | 0 |
| Amortization of debt discount and deferred financing costs | 0 | 194 |
| Interest on notes - non-cash-Exchangeable Senior Subordinated Notes Due Two Thousand Twenty Five | 0 | 88 |
| Financing transaction costs included in financing activities | 0 | - |
| Interest on notes - non-cash-Promissory Note | 562 | 853 |
| Adjustments to fair value of derivatives | -673 | -1,134 |
| Other | -880 | -940 |
| Accounts receivable | 448 | - |
| Prepaid expenses and other current assets | 984 | 1,212 |
| Inventory | 201 | 948 |
| Accounts payable | -612 | 938 |
| Accrued expenses | 1,343 | 1,299 |
| Income taxes | -89 | 54 |
| Other liabilities | 0 | -568 |
| Net cash used in operating activities | -7,447 | -7,811 |
| Purchases of property and equipment | 12 | 2 |
| Purchases of short-term investments | 0 | 0 |
| Proceeds from sale of short-term investments | 0 | 0 |
| Net cash (used in) / provided by investing activities | -12 | -2 |
| Repayment of exchangeable notes | 0 | 14,745 |
| Proceeds from issuance of ordinary shares, net of transaction costs | 5,432 | 11,477 |
| Net cash provided by financing activities | 5,432 | -3,268 |
| Effect of exchange rates on cash and cash equivalents | -2 | -18 |
| Net (decrease) / increase in cash, cash equivalents and restricted cash | -2,029 | -11,099 |
| Cash and cash equivalents at beginning of period | 24,159 | - |
| Cash and cash equivalents at end of period | 11,031 | - |
Iterum Therapeutics plc (ITRM)
Iterum Therapeutics plc (ITRM)